Prostate cancer
Conditions
Interventions
Silodosin
Silodosin plus Tadalafil
Sponsors
Nara Medical University
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: 1, cT1-T3aN0M0 prostate cancer diagnosed by prostate biopsy, technetium-99 m [99 m-Tc] bone scans, computed tomography, and magnetic resonance imaging 2, Adult men aged 20-80 years 3, Performance Status 0-2 4, Men who undergo 125I-brachytherapy for prostate cancer 5, Prostate volume > 15mL based on MRI before treatment
Exclusion criteria
Exclusion criteria: 1 Patients who take nitric acid agents 2 Allergy to tadalafil 3 Unstable angina 4 Heart failure NYHA3 or more 5 Uncontrolled arrhythmia or hypotension 6 Myocardial infarction within 3 months 7 Cerebral infarction or hemorrhage within 6 months 8 Patients who take PDE 5 inhibitor 9 Ineligibility judged by the investigator due to medical, psychological or other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change in mean 24-hour urinary frequency for 3 days at 3 months after I125 brachytherapy from baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| The changes in IPSS, OABSS, and EPIC score; post-voiding residual urine; and mean volume voided per micturition from baseline at 3 months after I125 brachytherapy urinary frequency for 3 days at 1 month and 3 months after I125 brachytherapy from baseline | — |
Countries
Japan
Contacts
Public ContactYasushi Nakai
Nara Medical University Department of Urology
Outcome results
None listed